β-D-N4-hydroxycytidine (NHC, EIDD-1931) inhibits chikungunya virus replication in mosquito cells and ex vivo Aedes aegypti guts, but not when ingested during blood-feeding
- 13 March 2024
- journal article
- research article
- Published by Elsevier in Antiviral Research
- Vol. 225, 105858
Abstract
No abstract availableKeywords
Funding Information
- University of Leuven
- Flanders Innovation and Entrepreneurship Agency
This publication has 31 references indexed in Scilit:
- Spatiotemporal dynamics and recurrence of chikungunya virus in Brazil: an epidemiological studyThe Lancet Microbe, 2023
- The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection modelEBioMedicine, 2021
- Fatal Outcome of Chikungunya Virus Infection in BrazilClinical Infectious Diseases, 2020
- Evaluation of sofosbuvir activity and resistance profile against West Nile virus in vitroAntiviral Research, 2020
- The prophylactic and therapeutic activity of a broadly active ribonucleoside analog in a murine model of intranasal venezuelan equine encephalitis virus infectionAntiviral Research, 2019
- Favipiravir as a potential countermeasure against neglected and emerging RNA virusesAntiviral Research, 2018
- Antiviral treatment efficiently inhibits chikungunya virus infection in the joints of mice during the acute but not during the chronic phase of the infectionAntiviral Research, 2018
- Cell-line dependent antiviral activity of sofosbuvir against Zika virusAntiviral Research, 2017
- Mutations in the chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviralJournal of Antimicrobial Chemotherapy, 2014
- Effect of Ivermectin onAnopheles gambiaeMosquitoes Fed on Humans: The Potential of Oral Insecticides in Malaria ControlThe Journal of Infectious Diseases, 2010